Thousands of women with advanced breast cancer in England and Wales are to be offered a “gamechanging” twice-a-day pill on the NHS after a U-turn by the medicines watchdog.
Experts hailed the decision as a “landmark moment”. As many as 3,000 women every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.
